Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial

This publication has 30 references indexed in Scilit:

• Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial
  The Lancet, 2009
• Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009
  Annals of Oncology, 2009
• Gene-Expression Signatures in Breast Cancer
  New England Journal of Medicine, 2009
• Competing Causes of Death From a Randomized Trial of Extended Adjuvant Endocrine Therapy for Breast Cancer
  JNCI Journal of the National Cancer Institute, 2008
• Estrogen-Receptor Status and Outcomes of Modern Chemotherapy for Patients With Node-Positive Breast Cancer
  JAMA, 2006
• REporting recommendations for tumour MARKer prognostic studies (REMARK)
  British Journal of Cancer, 2005
• Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
  The Lancet, 2005
• A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
  New England Journal of Medicine, 2004
• A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
  New England Journal of Medicine, 2002
• Flexible parametric proportional‐hazards and proportional‐odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects
  Statistics in Medicine, 2002